AF
ACRS icon

Amalgamated Financial’s Aclaris Therapeutics ACRS Stock Holding History

Amalgamated Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$143K Buy
+8,306
New +$113K ﹤0.01% 2018

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Amalgamated Financial's ACRS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Aclaris Therapeutics (ACRS) in Q1 2022: 8,306 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #2018 among its holdings.

109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Amalgamated Financial held 8,306 shares of Aclaris Therapeutics worth $143K as of Q1 2022.
  • Aclaris Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Aclaris Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2018 holding.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.